Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod in relapsing remitting multiple sclerosis (phase 2, MRI-based efficacy)
2004-003943-28Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laquinimod in multiple sclerosis (MS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Cumulative number of enhancing T1 lesions on MRI. Started Dec 2004; status: completed.
02
Drugs
laquinimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2004-003943-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003943-28.